SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934
(Amendment No.   )*

Cellegy Pharmaceuticals, Inc.
-----------------------------------------
(Name of Issuer)

Common Stock
-----------------------------------------
(Title of Class of Securities)

15115L-10-3
-----------------------------------------
(CUSIP Number)

Check the following box if a fee is being paid with this statement [x].
(A fee is not required only if the filing person: (1) has a previous
statement on file reporting beneficial ownership of more than five
percent of the class of securities described in Item 1; and (2) has
no amendment subsequent thereto reporting beneficial ownership of five
percent or less of such class.) (See Rule 13d-7.)

*The remainder of this cover page shall be filled out for a reporting
person's initial filing on this form with respect to the subject class
of securities, and for any subsequent amendment containing information
which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not
be deemed to be "filed" for the purpose of Section 18 of the
Securities Exchange Act of 1934 ("Act") or otherwise subject to the
liabilities of that section of the Act but shall be subject to all
other provisions of the Act (however, see the Notes).

(Continued on following page(s))

Page 1 of 7 Pages

CUSIP NO. 15115L-10-3                13G                   PAGE  2  OF 7  PAGES

1    NAME OF REPORTING PERSON
S.S OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

Neutrogena Corporation
95-2221471

2    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

(a) [ ]
(b) [ X ]

3    SEC USE ONLY

4    CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware

5 SOLE VOTING POWER
0

6 SHARED VOTING POWER

475,560

7 SOLE DISPOSITIVE POWER
0

8 SHARED DISPOSITIVE POWER
475,560

9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
475,560

10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES *

11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
12.61%

12 TYPE OF REPORTING PERSON*
CO

*SEE INSTRUCTION BEFORE FILLING OUT!

3 CUSIP NO. 15115L-10-3 13G PAGE 3 OF 7 PAGES

1 NAME OF REPORTING PERSON
S.S OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

Johnson & Johnson
22-1024240

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
(a) [ ]
(b) [ X ]

3 SEC USE ONLY

4 CITIZENSHIP OR PLACE OF ORGANIZATION
New Jersey

5 SOLE VOTING POWER
NUMBER OF SHARED VOTING POWER SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

6  475,560

7  SOLE DISPOSITIVE POWER

0

8  SHARED DISPOSITIVE POWER

475,560

9  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

475,560

10  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES *

11  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

12.61%

12  TYPE OF REPORTING PERSON*

CO

*SEE INSTRUCTION BEFORE FILLING OUT!

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 10549

--------------------------------- SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934

Item 1.   (a).  Name of Issuer: Cellegy Pharmaceuticals, Inc.

   (b).  Address of Issuer's Principal Executive Offices: 371 Bel Marin Keys
   Novato, CA 94949

Item 2.   (a).  Name of Person Filing: Johnson & Johnson
   Neutrogena Corporation
Item 2. (c) Citizenship:
Johnson & Johnson - New Jersey
Neutrogena Corporation - Delaware

(d) Title of Class of Securities:
Common Stock

(e) CUSIP Number:
15115L-10-3

Item 3. This statement is filed pursuant to Rule by
Not applicable

Item 4. Ownership.

(a) Amount Beneficially Owned
Each corporation beneficially owns 475,560 shares

(b) Percent of Class:
12.61%

(c) Number of Shares as to which each such person has:

(i) sole power to vote or to direct the vote 0
(ii) shared power to vote or to direct the vote 475,560
(iii) sole power to dispose or to direct the disposition of 0
(iv) shared power to dispose or to direct the disposition of 475,560

Item 5. Ownership of Five Percent or Less of a Class:
Not applicable.

Item 6. Ownership of More Than Five Percent on Behalf of Another Person:
Not applicable.
Item 7. Identification and Classification of Subsidiaries which Acquired the Security Being Reported on by the Parent Holding Company:

Not applicable.

Item 8. Identification and Classification of Members of the Group:

Not applicable.

Item 9. Notice of Dissolution of Group:

Not applicable.

Item 10. Certification:

Not applicable.

Signature: After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

JOHNSON & JOHNSON

By: /s/ James R. Utaski

Name/Title: James R. Utaski
Vice President

NEUTROGENA CORPORATION

By: /s/ Clay H. Paterson

Name/Title: Clay H. Paterson
Secretary

Dated: February 13, 1996

Page 7 of 7 Pages